Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143840
Corporate User License Price USD 6000
Corporate User License Price INR 431520
Site License Price USD 4000
Site License Price INR 287680
Request a Quote

Report Title

Dementia-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Dementia-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Dementia-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Dementia-Pipeline Review, H2 2016



Executive Summary

Dementia-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Dementia-Pipeline Review, H2 2016', provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dementia

The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects

The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dementia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dementia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Dementia Overview 10

Therapeutics Development 11

Pipeline Products for Dementia-Overview 11

Pipeline Products for Dementia-Comparative Analysis 12

Dementia-Therapeutics under Development by Companies 13

Dementia-Therapeutics under Investigation by Universities/Institutes 16

Dementia-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Dementia-Products under Development by Companies 21

Dementia-Products under Investigation by Universities/Institutes 25

Dementia-Companies Involved in Therapeutics Development 26

Adamas Pharmaceuticals, Inc. 26

AgeneBio Inc. 27

Alector LLC 28

AlzProtect SAS 29

Amarantus Bioscience Holdings, Inc. 30

Anavex Life Sciences Corp. 31

Axon Neuroscience SE 32

Axovant Sciences Ltd. 33

BioArctic Neuroscience AB 34

Biogen Inc 35

Biotie Therapies Corp. 36

Boehringer Ingelheim GmbH 37

Chase Pharmaceuticals Corporation 38

Cortice Biosciences, Inc. 39

Daewoong Pharmaceutical Co., Ltd. 40

Eisai Co., Ltd. 41

Eli Lilly and Company 42

FORUM Pharmaceuticals Inc. 43

H. Lundbeck A/S 44

Heptares Therapeutics Limited 45

Hyundai Pharmaceutical Co., Ltd. 46

Ildong Pharmaceutical Co., Ltd. 47

Immungenetics AG 48

ImStar Therapeutics Inc. 49

Integrative Research Laboratories Sweden AB 50

Intellect Neurosciences, Inc. 51

Intra-Cellular Therapies, Inc. 52

INVENT Pharmaceuticals, Inc. 53

M3 Biotechnology, Inc. 54

MediPost Co., Ltd. 55

Neuraltus Pharmaceuticals, Inc. 56

Neurimmune Holding AG 57

Neurodyn Inc. 58

Oryzon Genomics SA 59

Otsuka Holdings Co., Ltd. 60

P2D Bioscience 61

Pacific Northwest Biotechnology, LLC 62

Pivot Pharmaceuticals Inc 63

Sinil Pharmaceutical Co., Ltd 64

Stelic Institute & Co., Inc. 65

Sumitomo Dainippon Pharma Co., Ltd. 66

Sylentis S.A.U. 67

Takeda Pharmaceutical Company Limited 68

TauRx Therapeutics Ltd. 69

Voyager Therapeutics, Inc. 70

WhanIn Pharmaceutical Co., Ltd. 71

Zhejiang Hisun Pharmaceutical Co., Ltd. 72

Dementia-Therapeutics Assessment 73

Assessment by Monotherapy Products 73

Assessment by Combination Products 74

Assessment by Target 75

Assessment by Mechanism of Action 78

Assessment by Route of Administration 81

Assessment by Molecule Type 83

Drug Profiles 85

(donepezil hydrochloride + memantine hydrochloride ER)-Drug Profile 85

(donepezil hydrochloride + solifenacin succinate)-Drug Profile 87

AADvac-1-Drug Profile 88

AD-35-Drug Profile 89

ANAVEX-371-Drug Profile 90

Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia-Drug Profile 92

ASN-561-Drug Profile 93

AVP-786-Drug Profile 94

AZP-2006-Drug Profile 97

BAN-0805-Drug Profile 99

BI-409306-Drug Profile 100

CB-2233-Drug Profile 102

CB-8411-Drug Profile 103

choline alfoscerate SR-Drug Profile 104

D-217-Drug Profile 105

dehydroevodiamine hydrochloride-Drug Profile 106

Drugs for Dementia-Drug Profile 107

Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia-Drug Profile 108

Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment-Drug Profile 109

DWJ-1365-Drug Profile 110

E-2609-Drug Profile 111

eltoprazine-Drug Profile 113

encenicline hydrochloride-Drug Profile 118

FRM-0334-Drug Profile 123

GIBH-130-Drug Profile 125

Gln-1062-Drug Profile 126

GTC-6000-Drug Profile 129

gugulipid-Drug Profile 130

HOB-075-Drug Profile 131

HTL-18318-Drug Profile 132

intepirdine-Drug Profile 133

INV-331-Drug Profile 135

IRL-752-Drug Profile 136

ITI-007-Drug Profile 137

levetiracetam-Drug Profile 145

LUAF-20513-Drug Profile 147

MM-201-Drug Profile 148

Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia-Drug Profile 149

Monoclonal Antibodies for Dementia and Alzheimer's Disease-Drug Profile 150

Monoclonal Antibodies to Inhibit Tau for CNS Disorders-Drug Profile 151

monosodium luminol-Drug Profile 152

NAT-Drug Profile 154

nelotanserin-Drug Profile 155

Neurostem-Drug Profile 157

NI-205-Drug Profile 159

NI-308-Drug Profile 160

NNC-269100-Drug Profile 161

NP-001-Drug Profile 162

ORY-2001-Drug Profile 165

P-003-Drug Profile 167

PD-2015-Drug Profile 168

PD-2016-Drug Profile 169

PD-2024-Drug Profile 170

PD-2244-Drug Profile 171

Peptide to Inhibit BACE for Cerebropathy and Dementia-Drug Profile 172

PST-900-Drug Profile 173

salicylamine-Drug Profile 174

SIN-1502-Drug Profile 175

Small Molecule for Dementia-Drug Profile 176

Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders-Drug Profile 177

Small Molecule to Activate LPL for CNS and Metabolic Disorders-Drug Profile 178

Small Molecule to Inhibit Glycogene 5 for Dementia-Drug Profile 179

Small Molecules for Frontotemporal Dementia-Drug Profile 180

Small Molecules for Ophthalmology and CNS Disorders-Drug Profile 181

Small Molecules to Agonize HGFR for CNS Disorders-Drug Profile 182

Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia-Drug Profile 183

Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia-Drug Profile 184

SND-14-Drug Profile 185

SYN-120-Drug Profile 186

Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders-Drug Profile 188

TAK-070-Drug Profile 189

TAK-071-Drug Profile 190

TauC-3-Drug Profile 191

tolfenamic acid-Drug Profile 192

TPI-287-Drug Profile 193

TRx-0237-Drug Profile 197

TTT-3002-Drug Profile 201

VYTAU-01-Drug Profile 202

WIB-1001C-Drug Profile 203

zonisamide-Drug Profile 204

Dementia-Dormant Projects 206

Dementia-Discontinued Products 211

Dementia-Product Development Milestones 212

Featured News & Press Releases 212

Appendix 226

Methodology 226

Coverage 226

Secondary Research 226

Primary Research 226

Expert Panel Validation 226

Contact Us 226

Disclaimer 227

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Dementia, H2 2016 17

Number of Products under Development for Dementia-Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Comparative Analysis by Unknown Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2016 31

Dementia-Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 32

Dementia-Pipeline by AgeneBio Inc., H2 2016 33

Dementia-Pipeline by Alector LLC, H2 2016 34

Dementia-Pipeline by AlzProtect SAS, H2 2016 35

Dementia-Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 36

Dementia-Pipeline by Anavex Life Sciences Corp., H2 2016 37

Dementia-Pipeline by Axon Neuroscience SE, H2 2016 38

Dementia-Pipeline by Axovant Sciences Ltd., H2 2016 39

Dementia-Pipeline by BioArctic Neuroscience AB, H2 2016 40

Dementia-Pipeline by Biogen Inc, H2 2016 41

Dementia-Pipeline by Biotie Therapies Corp., H2 2016 42

Dementia-Pipeline by Boehringer Ingelheim GmbH, H2 2016 43

Dementia-Pipeline by Chase Pharmaceuticals Corporation, H2 2016 44

Dementia-Pipeline by Cortice Biosciences, Inc., H2 2016 45

Dementia-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 46

Dementia-Pipeline by Eisai Co., Ltd., H2 2016 47

Dementia-Pipeline by Eli Lilly and Company, H2 2016 48

Dementia-Pipeline by FORUM Pharmaceuticals Inc., H2 2016 49

Dementia-Pipeline by H. Lundbeck A/S, H2 2016 50

Dementia-Pipeline by Heptares Therapeutics Limited, H2 2016 51

Dementia-Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 52

Dementia-Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016 53

Dementia-Pipeline by Immungenetics AG, H2 2016 54

Dementia-Pipeline by ImStar Therapeutics Inc., H2 2016 55

Dementia-Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 56

Dementia-Pipeline by Intellect Neurosciences, Inc., H2 2016 57

Dementia-Pipeline by Intra-Cellular Therapies, Inc., H2 2016 58

Dementia-Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 59

Dementia-Pipeline by M3 Biotechnology, Inc., H2 2016 60

Dementia-Pipeline by MediPost Co., Ltd., H2 2016 61

Dementia-Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2016 62

Dementia-Pipeline by Neurimmune Holding AG, H2 2016 63

Dementia-Pipeline by Neurodyn Inc., H2 2016 64

Dementia-Pipeline by Oryzon Genomics SA, H2 2016 65

Dementia-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 66

Dementia-Pipeline by P2D Bioscience, H2 2016 67

Dementia-Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016 68

Dementia-Pipeline by Pivot Pharmaceuticals Inc, H2 2016 69

Dementia-Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016 70

Dementia-Pipeline by Stelic Institute & Co., Inc., H2 2016 71

Dementia-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 72

Dementia-Pipeline by Sylentis S.A.U., H2 2016 73

Dementia-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 74

Dementia-Pipeline by TauRx Therapeutics Ltd., H2 2016 75

Dementia-Pipeline by Voyager Therapeutics, Inc., H2 2016 76

Dementia-Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016 77

Dementia-Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2016 78

Assessment by Monotherapy Products, H2 2016 79

Assessment by Combination Products, H2 2016 80

Number of Products by Stage and Target, H2 2016 82

Number of Products by Stage and Mechanism of Action, H2 2016 85

Number of Products by Stage and Route of Administration, H2 2016 88

Number of Products by Stage and Molecule Type, H2 2016 90

Dementia-Dormant Projects, H2 2016 212

Dementia-Dormant Projects (Contd..1), H2 2016 213

Dementia-Dormant Projects (Contd..2), H2 2016 214

Dementia-Dormant Projects (Contd..3), H2 2016 215

Dementia-Dormant Projects (Contd..4), H2 2016 216

Dementia-Discontinued Products, H2 2016 217

List of Figures

Number of Products under Development for Dementia, H2 2016 17

Number of Products under Development for Dementia-Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 79

Assessment by Combination Products, H2 2016 80

Number of Products by Top 10 Targets, H2 2016 81

Number of Products by Stage and Top 10 Targets, H2 2016 81

Number of Products by Top 10 Mechanism of Actions, H2 2016 84

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 84

Number of Products by Routes of Administration, H2 2016 87

Number of Products by Stage and Routes of Administration, H2 2016 87

Number of Products by Molecule Types, H2 2016 89

Number of Products by Stage and Top 10 Molecule Types, H2 2016 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Adamas Pharmaceuticals, Inc.

AgeneBio Inc.

Alector LLC

AlzProtect SAS

Amarantus Bioscience Holdings, Inc.

Anavex Life Sciences Corp.

Axon Neuroscience SE

Axovant Sciences Ltd.

BioArctic Neuroscience AB

Biogen Inc

Biotie Therapies Corp.

Boehringer Ingelheim GmbH

Chase Pharmaceuticals Corporation

Cortice Biosciences, Inc.

Daewoong Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

Eli Lilly and Company

FORUM Pharmaceuticals Inc.

H. Lundbeck A/S

Heptares Therapeutics Limited

Hyundai Pharmaceutical Co., Ltd.

Ildong Pharmaceutical Co., Ltd.

Immungenetics AG

ImStar Therapeutics Inc.

Integrative Research Laboratories Sweden AB

Intellect Neurosciences, Inc.

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

M3 Biotechnology, Inc.

MediPost Co., Ltd.

Neuraltus Pharmaceuticals, Inc.

Neurimmune Holding AG

Neurodyn Inc.

Oryzon Genomics SA

Otsuka Holdings Co., Ltd.

P2D Bioscience

Pacific Northwest Biotechnology, LLC

Pivot Pharmaceuticals Inc

Sinil Pharmaceutical Co., Ltd

Stelic Institute & Co., Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sylentis S.A.U.

Takeda Pharmaceutical Company Limited

TauRx Therapeutics Ltd.

Voyager Therapeutics, Inc.

WhanIn Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd.

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand